These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15592197)

  • 1. Magnetic resonance molecular imaging with nanoparticles.
    Lanza GM; Winter PM; Caruthers SD; Morawski AM; Schmieder AH; Crowder KC; Wickline SA
    J Nucl Cardiol; 2004; 11(6):733-43. PubMed ID: 15592197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions.
    Lanza GM; Winter PM; Caruthers SD; Hughes MS; Hu G; Schmieder AH; Wickline SA
    Angiogenesis; 2010 Jun; 13(2):189-202. PubMed ID: 20411320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron oxide MR contrast agents for molecular and cellular imaging.
    Bulte JW; Kraitchman DL
    NMR Biomed; 2004 Nov; 17(7):484-99. PubMed ID: 15526347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MR techniques for in vivo molecular and cellular imaging.
    Delikatny EJ; Poptani H
    Radiol Clin North Am; 2005 Jan; 43(1):205-20. PubMed ID: 15693657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted ultrasonic contrast agents for molecular imaging and therapy.
    Lanza GM; Wickline SA
    Curr Probl Cardiol; 2003 Dec; 28(12):625-53. PubMed ID: 14691443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted ultrasonic contrast agents for molecular imaging and therapy.
    Lanza GM; Wickline SA
    Prog Cardiovasc Dis; 2001; 44(1):13-31. PubMed ID: 11533924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles.
    Yang H; Zhuang Y; Sun Y; Dai A; Shi X; Wu D; Li F; Hu H; Yang S
    Biomaterials; 2011 Jul; 32(20):4584-93. PubMed ID: 21458063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.
    Ghaghada KB; Ravoori M; Sabapathy D; Bankson J; Kundra V; Annapragada A
    PLoS One; 2009 Oct; 4(10):e7628. PubMed ID: 19893616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery.
    Lanza GM; Winter P; Caruthers S; Schmeider A; Crowder K; Morawski A; Zhang H; Scott MJ; Wickline SA
    Curr Pharm Biotechnol; 2004 Dec; 5(6):495-507. PubMed ID: 15579039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbon nanostructures as a new high-performance platform for MR molecular imaging.
    Hartman KB; Wilson LJ
    Adv Exp Med Biol; 2007; 620():74-84. PubMed ID: 18217336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents.
    Kim BH; Lee N; Kim H; An K; Park YI; Choi Y; Shin K; Lee Y; Kwon SG; Na HB; Park JG; Ahn TY; Kim YW; Moon WK; Choi SH; Hyeon T
    J Am Chem Soc; 2011 Aug; 133(32):12624-31. PubMed ID: 21744804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
    Marasini R; Thanh Nguyen TD; Aryal S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target-specific paramagnetic and superparamagnetic micelles for molecular MR imaging.
    Straathof R; Strijkers GJ; Nicolay K
    Methods Mol Biol; 2011; 771():691-715. PubMed ID: 21874503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-Based Paramagnetic Contrast Agents for Magnetic Resonance Imaging.
    Pellico J; Ellis CM; Davis JJ
    Contrast Media Mol Imaging; 2019; 2019():1845637. PubMed ID: 31191182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging concepts in molecular MRI.
    Sosnovik DE; Weissleder R
    Curr Opin Biotechnol; 2007 Feb; 18(1):4-10. PubMed ID: 17126545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
    Neuwelt EA; Várallyay P; Bagó AG; Muldoon LL; Nesbit G; Nixon R
    Neuropathol Appl Neurobiol; 2004 Oct; 30(5):456-71. PubMed ID: 15488022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring cell therapy using iron oxide MR contrast agents.
    Bulte JW; Kraitchman DL
    Curr Pharm Biotechnol; 2004 Dec; 5(6):567-84. PubMed ID: 15579045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast agents: magnetic resonance.
    Burtea C; Laurent S; Vander Elst L; Muller RN
    Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular magnetic resonance imaging with targeted contrast agents.
    Artemov D
    J Cell Biochem; 2003 Oct; 90(3):518-24. PubMed ID: 14523986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.